| 1 | Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes | Diabetes, Obesity and Metabolism | 2013 | 676 |
| 2 | Incretin hormones: Their role in health and disease | Diabetes, Obesity and Metabolism | 2018 | 661 |
| 3 | Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension | Diabetes, Obesity and Metabolism | 2022 | 623 |
| 4 | Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c | Diabetes, Obesity and Metabolism | 2010 | 579 |
| 5 | Pancreatic β‐cell mass in European subjects with type 2 diabetes | Diabetes, Obesity and Metabolism | 2008 | 574 |
| 6 | An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines | Diabetes, Obesity and Metabolism | 2020 | 543 |
| 7 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Diabetes, Obesity and Metabolism | 2013 | 526 |
| 8 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial | Diabetes, Obesity and Metabolism | 2007 | 511 |
| 9 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors | Diabetes, Obesity and Metabolism | 2012 | 487 |
| 10 | Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women | Diabetes, Obesity and Metabolism | 2006 | 462 |
| 11 | Adiponectin – a key adipokine in the metabolic syndrome | Diabetes, Obesity and Metabolism | 2006 | 461 |
| 12 | Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity | Diabetes, Obesity and Metabolism | 2017 | 459 |
| 13 | Insulin‐associated weight gain in diabetes – causes, effects and coping strategies | Diabetes, Obesity and Metabolism | 2007 | 437 |
| 14 | Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin | Diabetes, Obesity and Metabolism | 2007 | 415 |
| 15 | Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Diabetes, Obesity and Metabolism | 2013 | 411 |
| 16 | Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Diabetes, Obesity and Metabolism | 2011 | 407 |
| 17 | Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2015 | 400 |
| 18 | Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis | Diabetes, Obesity and Metabolism | 2018 | 390 |
| 19 | Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis | Diabetes, Obesity and Metabolism | 2016 | 389 |
| 20 | Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin | Diabetes, Obesity and Metabolism | 2014 | 380 |
| 21 | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia | Diabetes, Obesity and Metabolism | 2012 | 365 |
| 22 | Role of vitamin D in the pathogenesis of type 2 diabetes mellitus | Diabetes, Obesity and Metabolism | 2008 | 351 |
| 23 | Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2006 | 342 |
| 24 | Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis | Diabetes, Obesity and Metabolism | 2017 | 341 |
| 25 | Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors | Diabetes, Obesity and Metabolism | 2016 | 330 |
| 26 | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial | Diabetes, Obesity and Metabolism | 2011 | 329 |
| 27 | Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications | Diabetes, Obesity and Metabolism | 2021 | 329 |
| 28 | Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial | Diabetes, Obesity and Metabolism | 2014 | 324 |
| 29 | Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis | Diabetes, Obesity and Metabolism | 2020 | 324 |
| 30 | Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes | Diabetes, Obesity and Metabolism | 2012 | 319 |
| 31 | Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease | Diabetes, Obesity and Metabolism | 2019 | 316 |
| 32 | Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity | Diabetes, Obesity and Metabolism | 2007 | 314 |
| 33 | Advanced glycation endproducts: what is their relevance to diabetic complications? | Diabetes, Obesity and Metabolism | 2007 | 293 |
| 34 | GLP‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence | Diabetes, Obesity and Metabolism | 2013 | 293 |
| 35 | Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review | Diabetes, Obesity and Metabolism | 2018 | 293 |
| 36 | The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity | Diabetes, Obesity and Metabolism | 2021 | 284 |
| 37 | The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update | Diabetes, Obesity and Metabolism | 2021 | 280 |
| 38 | Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature | Diabetes, Obesity and Metabolism | 2010 | 279 |
| 39 | Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials | Diabetes, Obesity and Metabolism | 2011 | 275 |
| 40 | Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials | Diabetes, Obesity and Metabolism | 2013 | 274 |
| 41 | Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults | Diabetes, Obesity and Metabolism | 2023 | 274 |
| 42 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials | Diabetes, Obesity and Metabolism | 2017 | 271 |
| 43 | Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls | Diabetes, Obesity and Metabolism | 2014 | 269 |
| 44 | Diabetes is an inflammatory disease: evidence from traditional Chinese medicines | Diabetes, Obesity and Metabolism | 2011 | 265 |
| 45 | The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus | Diabetes, Obesity and Metabolism | 2012 | 264 |
| 46 | Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes | Diabetes, Obesity and Metabolism | 2012 | 264 |
| 47 | New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3) | Diabetes, Obesity and Metabolism | 2015 | 260 |
| 48 | Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial | Diabetes, Obesity and Metabolism | 2011 | 259 |
| 49 | Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial | Diabetes, Obesity and Metabolism | 2009 | 250 |
| 50 | Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects | Diabetes, Obesity and Metabolism | 2011 | 250 |
